Scientists engineer CAR-NK immune cells directly inside the body using mRNA nanoparticles

How the In-Body Cell Engineering Works

Researchers have developed a new approach to create chimeric antigen receptor natural killer (CAR-NK) cells within living tissues. The method uses lipid nanoparticle delivery of messenger RNA directly into the body, bypassing traditional laboratory cell engineering.

The technique involves encapsulating CAR-coding mRNA into lipid nanoparticles and injecting them into target tissues. Once inside cells, these nanoparticles release their mRNA cargo into the cytoplasm, where it gets translated into chimeric antigen receptor proteins. This process reprograms natural killer cells to target specific diseases, particularly cancer.

Unlike conventional CAR-NK therapies that require extracting cells from patients, genetically modifying them in labs, and reinfusing them, this new method performs the engineering directly inside the body. The lipid nanoparticles act as protective vehicles, delivering functional mRNA to cells that then produce therapeutic proteins. This approach could dramatically reduce treatment complexity and cost while expanding access to personalized immunotherapies.

What Are the Potential Medical Applications?

The in situ generation of CAR-NK cells represents a significant shift from current cell therapy paradigms. Traditional methods are time-consuming, expensive, and require specialized facilities. By contrast, this mRNA-based approach leverages the body's own cellular machinery to produce therapeutic immune cells where they're needed most.

The technology could transform treatment for blood cancers, solid tumors, and autoimmune diseases. CAR-NK cells engineered through this method would circulate throughout the body, seeking and destroying cancer cells while sparing healthy tissue. Early research suggests these in-body generated cells may be more effective than lab-created versions because they develop in their natural tissue environment.

Clinical trials are likely years away, but the approach addresses major limitations of existing CAR-T cell therapies, including severe side effects and manufacturing delays. Researchers believe this method could make immunotherapy accessible to more patients worldwide.

The development marks a promising step toward next-generation cancer treatments that combine the precision of targeted therapy with the convenience of simple injections.

Frequently Asked Questions

What makes CAR-NK cells different from CAR-T cells? CAR-NK cells use natural killer cells instead of T-cells, potentially reducing dangerous immune reactions while maintaining anti-cancer activity.

How do lipid nanoparticles protect mRNA? The fatty particles shield fragile mRNA from degradation in the body and help it enter target cells efficiently.

Can this approach treat solid tumors? Early evidence suggests in situ CAR-NK generation may overcome barriers that limit current immunotherapies against solid cancers.